The prognostic value of different molecular predictors on overall and progression free survival was investigated.
Progression free survival and overall survival of patients with glioblastoma dependent on TP53 mutation,
p53 immunoreactivity, epidermal growth factor receptor, cyclin-dependent kinase CDK 4 or murine double minute 2 amplification, CDKN2A homozygous deletion, allelic losses on chromosome arms
1p, 9p, 10q, and 19q, O6-methylguanine methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutations
Fresh-frozen tissue and blood samples were obtained from 301 patients with microsurgical tumor resection and clinical
follow-up information was collected.